Prognostic Role of Serum Vascular Endothelial Growth Factor and Hepatocyte Growth Factor Post Stereotactic Body Radiation in Advanced Hepatocellular Carcinoma

Overview

Journal J Clin Exp Hepatol

Publisher Elsevier

Specialty Gastroenterology

Date 2024 Dec 10

PMID 39654812

Authors

Prabhjyoti Pahwa

Deepti Sharma

Pushpa Yadav

Sherin S Thomas

Sandhya Hora

E Preedia Babu

Gayatri Ramakrishna

Shiv K Sarin

Nirupama Trehanpati

Affiliations

Soon will be listed here.

Abstract

Background/aims: Stereotactic body radiation therapy (SBRT) has evolved as a treatment alternative for advanced hepatocellular carcinoma (HCC) patients who are ineligible for other local therapies. Posttreatment responses are assessed by imaging modalities, serum AFP, and protein induced by vitamin K absence-II (PIVKA) II levels. Despite good specificity, both AFP and PIVKA-II have low to medium sensitivity. The study aimed to find more effective biomarkers that have an impact on the survival outcomes of the patients.

Methods: We have prospectively collected blood samples from 18 patients undergoing SBRT. Serum levels of hepatocyte growth factor (HGF) and vascular endothelial growth factor-A (VEGF-A) were analyzed kinetically pre-SBRT following day 5 and day 30 post-SBRT. Local control (LC), overall survival (OS), progression free survival (PFS), and postprocedure adverse events were recorded.

Results: The cohort had a median follow-up duration of 12.5 months (range 4-30 months). In the entire cohort, the estimated mean OS was 21.2 months (95% confidence interval [CI], 15.9-26.4), and the median progression free survival (mPFS) was 8 months (95% CI, 1.7-14.2). Patients with higher PIVKA-II levels (pre- and post-SBRT) also showed increased concentrations of VEGF-A and HGF. Patients with metastasis at presentation had higher HGF ( = 0.028) and VEGF-A ( = 0.027) concentrations compared to the nonmetastatic group. Patients with increased levels of VEGF-A and HGF at day 30 post-SBRT compared to day 5 had poor PFS. Indeed, the mPFS was 22 months vs 6 months ( = 0.301) in patients with low VEGF-A post SBRT on day 30 compared to day 5. Similarly, mPFS in patients with increase in HGF was 6 months as compared to 22 months ( = 0.326) in patients in whom HGF was reduced post-SBRT.

Conclusion: We conclude that in addition to PIVKA-II, HGF, and VEGF-A can be used as prognostic and predictive markers for early progression of disease post-SBRT. However, further prospective trials are warranted in the future to validate the results.

References

Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View

Sagar V, Herring K, Curbishley S, Hodson J, Fletcher P, Karkhanis S . The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study. Oncotarget. 2021; 12(24):2338-2350. PMC: 8629402. DOI: 10.18632/oncotarget.28136. View

Dawson L, McGinn C, Normolle D, Ten Haken R, Walker S, Ensminger W . Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000; 18(11):2210-8. DOI: 10.1200/JCO.2000.18.11.2210. View

Omar M, Omran M, Farid K, Tabll A, Shahein Y, Emran T . Biomarkers for Hepatocellular Carcinoma: From Origin to Clinical Diagnosis. Biomedicines. 2023; 11(7). PMC: 10377276. DOI: 10.3390/biomedicines11071852. View

Sharma D, Khosla D, Meena B, Yadav H, Kapoor R . Exploring the Evolving Landscape of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma. J Clin Exp Hepatol. 2024; 15(1):102386. PMC: 11399579. DOI: 10.1016/j.jceh.2024.102386. View

Alvarez-Mercado A, Caballeria-Casals A, Rojano-Alfonso C, Chavez-Reyes J, Mico-Carnero M, Sanchez-Gonzalez A . Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection. Biomedicines. 2021; 9(9). PMC: 8470173. DOI: 10.3390/biomedicines9091158. View

Hamzah N, Kassim N, Omar J, Abdullah M, Lee Y . Levels of PIVKA-II and alpha-fetoprotein in unresectable hepatocellular carcinoma compared to healthy controls and predictive values of both markers with radiological responses after loco-regional interventions. PeerJ. 2023; 11:e15988. PMC: 10538296. DOI: 10.7717/peerj.15988. View

Matsuo Y . Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview. Curr Oncol. 2023; 30(2):2493-2500. PMC: 9956001. DOI: 10.3390/curroncol30020190. View

Cuneo K, Devasia T, Sun Y, Schipper M, Karnak D, Davis M . Serum Levels of Hepatocyte Growth Factor and CD40 Ligand Predict Radiation-Induced Liver Injury. Transl Oncol. 2019; 12(7):889-894. PMC: 6514276. DOI: 10.1016/j.tranon.2019.04.003. View

10.

Kim B, Park H, Kim T, Koh Y, Hong J, Cho Y . Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study. JHEP Rep. 2024; 6(4):100991. PMC: 10920711. DOI: 10.1016/j.jhepr.2023.100991. View

11.

Kumar A, Acharya S, Singh S, Duseja A, Madan K, Shukla A . 2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations. J Clin Exp Hepatol. 2023; 14(1):101269. PMC: 10724697. DOI: 10.1016/j.jceh.2023.08.005. View

12.

Sun X, Wu Z, Liao X, Yuan J . Tumor angiogenesis and its clinical significance in pediatric malignant liver tumor. World J Gastroenterol. 2005; 11(5):741-3. PMC: 4250752. DOI: 10.3748/wjg.v11.i5.741. View

13.

Liu K, Min X, Peng J, Yang K, Yang L, Zhang X . The Changes of HIF-1α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. J Clin Med Res. 2016; 8(4):297-302. PMC: 4780492. DOI: 10.14740/jocmr2496w. View

14.

Poon R, Ho J, Tong C, Lau C, Ng I, Fan S . Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004; 91(10):1354-60. DOI: 10.1002/bjs.4594. View

15.

Sharma D, Thaper D, Kamal R, Yadav H . Role of palliative SBRT in barcelona clinic liver cancer-stage C hepatocellular carcinoma patients. Strahlenther Onkol. 2023; 199(9):838-846. DOI: 10.1007/s00066-023-02065-x. View

16.

Yao D, Wu X, Zhu Y, Shi G, Dong Z, Yao D . Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2005; 4(2):220-6. View

17.

Van Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R . Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation. 1998; 97(4):381-90. DOI: 10.1161/01.cir.97.4.381. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

20.

Tian S, Chen Y, Zhang Y, Xu X . Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma. J Clin Lab Anal. 2022; 37(1):e24823. PMC: 9833986. DOI: 10.1002/jcla.24823. View